Use of adelmidrol and other topical or oral cannabinomimetic or aliamide mast cell inhibitors to treat dermatoheliosis, seborrheic keratoses, and androgenetic alopecia

US10143639B2 · kind B2 · utility

Inventor

• William Robert McDaniel · Shrewsbury, US

Key dates

• Filing date: Mar 22, 2017
• Grant date: Dec 4, 2018
• Expiry date: Apr 22, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61Q19/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of correcting the visible and microscopic signs of Dermatoheliosis (chronic ultraviolet light-damaged human skin) and its various clinical manifestations (wrinkling, sagging, fragility, melasma, Poikiloderma of Civatte, solar lentigines, and senile purpura) and also Androgenetic Alopecia and Seborrheic Keratoses consists of the administration of fatty acid derivatives capable of inhibiting mast cells and the mediators they release that cause local tissue damage. These fatty acid derivatives include palmitoylethanolamide (PEA) and related cannabinomimetic compounds and adelmidrol and related Autacoid Local Injury Antagonist amides (ALIAmides) which are administered orally or applied topically. Adelmidrol, the best absorbed topically, is applied in a concentration of between 1% and 10% by volume, with a preferred concentration of about 5% by volume. Normally produced in body tissues in response to the effects of painful and inflammatory mast cell mediators, these compounds must be added in these conditions to stop the progression of damage because the affected tissues lack inflammation due to the immunosuppressive effects of the chronic ultraviolet radiation that initiates a…